Past, present, and future for biologic intervention in atopic dermatitis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Allergy. European Journal of Allergy and Clinical Immunology

• Publication date

  2015-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/all.12632PMID 25879391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma

  2014cited by this paper
• Ustekinumab in the Treatment of Severe Atopic Dermatitis: A Preliminary Report of Our Experience With 4 Patients

  2014cited by this paper
• The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases.

  2014cited by this paper
• Th2 cytokines increase Staphylococcus aureus alpha toxin induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6)

  2014cited by this paper
• Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

  2014cited by this paper
• The Plasma Cell Signature in Autoimmune Disease

  2014cited by this paper
• Ustekinumab en el tratamiento de la dermatitis atópica severa. Nuestra experiencia en 4 pacientes. Informe preliminar

  2014cited by this paper
• Increased efficacy of omalizumab in atopic dermatitis patients with wild‐type filaggrin status and higher serum levels of phosphatidylcholines

  2014cited by this paper
• Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012.

  2014cited by this paper
• Immunologic Effects of Omalizumab in Children With Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial

  2014cited by this paper
• Staphylococcus δ-toxin promotes mouse allergic skin disease by inducing mast cell degranulation

  2013cited by this paper
• Staphylococcus aureus Colonization in Acute and Chronic Skin Lesions of Patients with Atopic Dermatitis

  2013cited by this paper
• Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases.

  2013cited by this paper
• The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis

  2013cited by this paper
• Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab

  2013cited by this paper
• A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis

  2013cited by this paper
• IL-13/IL-22-coproducing T cells, a novel subset, are increased in atopic dermatitis.

  2013influential reference
• Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial

  2013cited by this paper
• Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study.

  2013cited by this paper
• The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch.

  2013cited by this paper
• Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.

  2013cited by this paper
• Rituximab for the treatment of rheumatoid arthritis: an update

  2013cited by this paper
• Update on systemic therapies for atopic dermatitis

  2012cited by this paper
• A prospective study in children with a severe form of atopic dermatitis: clinical outcome in relation to cytokine gene polymorphisms.

  2012influential reference
• Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis.

  2012cited by this paper
• Systemic treatment of adult atopic dermatitis.

  2012cited by this paper
• The differences in the involvements of loci of promoter region and Ile50Val in interleukin-4 receptor α chain gene between atopic dermatitis and Japanese cedar pollinosis.

  2012cited by this paper
• Crohn’s Disease

  2012cited by this paper
• The Role of T‐Regulatory Cells and Toll‐Like Receptors 2 and 4 In Atopic Dermatitis

  2012cited by this paper
• Treatment of severe refractory adult atopic dermatitis with ustekinumab

  2012cited by this paper
• Supplemental Fig. 1

  2012cited by this paper
• IL‐31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis

  2012cited by this paper
• Epidemiology of atopic dermatitis: a review.

  2012cited by this paper
• Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor

  2012cited by this paper
• An association of TLR2–16934A>T polymorphism and severity/phenotype of atopic dermatitis

  2011cited by this paper
• The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma

  2011cited by this paper
• Possible pathogenic role of Th17 cells for atopic dermatitis

  2011cited by this paper
• The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections.

  2011cited by this paper
• Combined occurrence of filaggrin mutations and IL‐10 or IL‐13 polymorphisms predisposes to atopic dermatitis

  2011cited by this paper
• Serum measurement of interleukin‐31 (IL‐31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring

  2011cited by this paper
• Filaggrin mutations associated with skin and allergic diseases.

  2011cited by this paper
• Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts.

  2011cited by this paper
• Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection.

  2011cited by this paper
• Skin Barrier Disruption - A Requirement for Allergen Sensitization?

  2011cited by this paper
• Antimicrobial Peptides Human β-Defensins and Cathelicidin LL-37 Induce the Secretion of a Pruritogenic Cytokine IL-31 by Human Mast Cells

  2010cited by this paper
• From atopic dermatitis to asthma: the atopic march.

  2010cited by this paper
• An update on the genetics of atopic dermatitis: scratching the surface in 2009.

  2010cited by this paper
• Superantigen-Induced Proliferation of Human CD4+CD25− T Cells Is Followed by a Switch to a Functional Regulatory Phenotype

  2010cited by this paper
• The influence of TSLP on the allergic response

  2010cited by this paper
• Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo‐controlled and double blind pilot study

  2010cited by this paper
• IL-4 Regulates Skin Homeostasis and the Predisposition toward Allergic Skin Inflammation

  2010influential reference
• IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells.

  2009cited by this paper
• Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy.

  2009cited by this paper
• Association of the toll‐like receptor 2 A‐16934T promoter polymorphism with severe atopic dermatitis

  2009cited by this paper
• Anti‐interleukin‐31‐antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis

  2009cited by this paper
• Thymic stromal lymphopoietin, OX40‐ligand, and interleukin‐25 in allergic responses

  2009cited by this paper
• Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum.

  2009cited by this paper
• Correlation of IL-31 serum levels with severity of atopic dermatitis.

  2008cited by this paper
• Atopic dermatitis.

  2008cited by this paper
• Genome-Wide Scan on Total Serum IgE Levels Identifies FCER1A as Novel Susceptibility Locus

  2008cited by this paper
• Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1

  2008cited by this paper
• Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment.

  2008cited by this paper
• TSLP acts on infiltrating effector T cells to drive allergic skin inflammation

  2008cited by this paper
• Intradermal Administration of Thymic Stromal Lymphopoietin Induces a T Cell- and Eosinophil-Dependent Systemic Th2 Inflammatory Response

  2008cited by this paper
• Chronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes

  2008cited by this paper
• Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.

  2008cited by this paper
• Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation.

  2008cited by this paper
• Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema.

  2008cited by this paper
• Association of staphylococcal superantigen-specific immunoglobulin e with mild and moderate atopic dermatitis.

  2008cited by this paper
• Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.

  2008cited by this paper
• Anti-CD20 (rituximab) treatment improves atopic eczema.

  2008cited by this paper
• Anti-CD20 (rituximab) treatment for atopic eczema.

  2008cited by this paper
• Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen.

  2008cited by this paper
• Possible pathogenic role of Th17 cells for atopic dermatitis.

  2008cited by this paper
• Cytokine modulation of atopic dermatitis filaggrin skin expression.

  2007cited by this paper
• IL-4 and IL-13 Negatively Regulate TNF-α- and IFN-γ-Induced β-Defensin Expression through STAT-6, Suppressor of Cytokine Signaling (SOCS)-1, and SOCS-31

  2007cited by this paper
• IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3.

  2007cited by this paper
• Crohn's disease: a review of current treatment with a focus on biologics.

  2007cited by this paper
• Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab.

  2007cited by this paper
• TH-17 cells in the circle of immunity and autoimmunity

  2007cited by this paper
• Efalizumab for severe atopic dermatitis: a pilot study in adults.

  2007cited by this paper
• IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis.

  2006cited by this paper
• Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

  2006cited by this paper
• Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab.

  2006cited by this paper
• Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations.

  2006cited by this paper
• Association of IL13 with total IgE: evidence against an inverse association of atopy and diabetes.

  2006cited by this paper
• Cathelicidin deficiency predisposes to eczema herpeticum.

  2006cited by this paper
• IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma.

  2006cited by this paper
• No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis Patients

  2006cited by this paper
• Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march.

  2006cited by this paper
• IL-31: a new link between T cells and pruritus in atopic skin inflammation.

  2006cited by this paper
• Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis

  2005cited by this paper
• Infliximab in the treatment of moderate to severe atopic dermatitis.

  2005cited by this paper
• IL-22 Inhibits Epidermal Differentiation and Induces Proinflammatory Gene Expression and Migration of Human Keratinocytes1

  2005cited by this paper
• Etanercept is minimally effective in 2 children with atopic dermatitis.

  2005cited by this paper
• Failure of omalizumab for treatment of severe adult atopic dermatitis.

  2005cited by this paper
• Topical Superantigen Exposure Induces Epidermal Accumulation of CD8+ T Cells, a Mixed Th1/Th2-Type Dermatitis and Vigorous Production of IgE Antibodies in the Murine Model of Atopic Dermatitis1

  2005cited by this paper
• Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin

  2005cited by this paper
• Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma.

  2004cited by this paper
• Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

  2004cited by this paper

• Mapping the Global Landscape of Biologics in Allergic Diseases: A Bibliometric Analysis.

  2026cites this paper
• Atopic Dermatitis at the European Academy of Dermatology and Venereology 2025: Updates and Insights

  2025cites this paper
• Pharmacologic inhibition of Il6st/gp130 improves dermatological inflammation and pruritus.

  2024cites this paper
• Immunological Advancements In Hand Eczema Treatment: Progress With Small Molecules and Biologics

  2024cites this paper
• Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis

  2023cites this paper
• T-helper-2 cells and atopic disease: lessons learnt from inborn errors of immunity.

  2023cites this paper
• Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis

  2022influential citation
• Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis

  2022cites this paper
• Mesenchymal Stem Cells Profile in Adult Atopic Dermatitis and Effect of IL4-IL13 Inflammatory Pathway Inhibition In Vivo: Prospective Case-Control Study

  2022cites this paper
• Galectin-9 contributes to the pathogenesis of atopic dermatitis via T cell immunoglobulin mucin-3

  2022cites this paper
• The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis

  2021cites this paper
• Endophenotype and Biomarker

  2021cites this paper
• Impact of Atopic Dermatitis and Chronic Hand Eczema on Quality of Life Compared with Other Chronic Diseases

  2020cites this paper
• The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta‐analysis

  2020cites this paper
• Atopic dermatitis: a review of evolving targeted therapies

  2019cites this paper
• Childhood atopic dermatitis: current developments, treatment approaches, and future expectations

  2019cites this paper
• Inflammation of the Skin and Its Therapeutic Targets

  2019cites this paper
• Understanding economic evidence for the prevention and treatment of atopic eczema

  2019cites this paper
• New and emerging targeted systemic therapies: a new era for atopic dermatitis

  2018cites this paper
• A systematic review of ustekinumab in the treatment of atopic dermatitis

  2018cites this paper
• Immune-modulation via IgD B-cell receptor suppresses allergic skin inflammation in experimental contact hypersensitivity models despite of a Th2-favoured humoral response.

  2018cites this paper
• Langerhans and inflammatory dendritic epidermal cells in atopic dermatitis are tolerized toward TLR2 activation

  2018cites this paper
• New biologics for allergic diseases

  2018influential citation
• Changing perspectives in atopic dermatitis.

  2017cites this paper
• Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany

  2017cites this paper
• A molecular mechanism for IL-4 suppression of loricrin transcription in epidermal keratinocytes: implication for atopic dermatitis pathogenesis

  2017influential citation
• Fc-fusion Proteins in Therapy: An Updated View.

  2017cites this paper
• Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?

  2017cites this paper
• Biological Therapeutic Treatment of Atopic Dermatitis

  2017influential citation
• Systemic Therapy of Atopic Dermatitis: When, How, for How Long?

  2017cites this paper
• Einsatz und Wirksamkeit von Systemtherapien bei Erwachsenen mit schwerer Neurodermitis: Erste Ergebnisse des deutschen Neurodermitis‐Registers TREATgermany

  2017cites this paper
• Anti-allergic and Profilaggrin (ProFLG)-mRNA expression modulatory effects of sacran.

  2017cites this paper
• Psoriasis and Atopic Dermatitis

  2017cites this paper
• Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

  2016cites this paper
• The adaptive immune system in atopic dermatitis and implications on therapy

  2016cites this paper
• Killing of Staphylococcus aureus via Magnetic Hyperthermia Mediated by Magnetotactic Bacteria

  2016cites this paper
• Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis

  2016cites this paper
• Economic evidence for the prevention and treatment of atopic eczema: a protocol for a systematic review

  2016cites this paper
• The Pathogenetic Effect of Natural and Bacterial Toxins on Atopic Dermatitis

  2016cites this paper
• IgE‐associated allergic disorders: recent advances in etiology, diagnosis, and treatment

  2016cites this paper
• Dermatite atopique et allergie alimentaire

  2016cites this paper
• Why we need a harmonized name for atopic dermatitis/atopic eczema/eczema!

  2016cites this paper
• Cellular and molecular immunologic mechanisms in patients with atopic dermatitis.

  2016cites this paper
• New opportunities and challenges in the assessment of drugs for atopic diseases

  2016cites this paper
• Barrier function and microbiotic dysbiosis in atopic dermatitis

  2015cites this paper
• SLAUGOS POREIKIAI IR TĖVŲ ŽINIOS APIE JŲ VAIKŲ ATOPINĮ DERMATITĄ: ANKETINĖS APKLAUSOS IR VIZUALINĖS ANALOGINĖS SKALĖS VERTINIMO DUOMENYS

  2015cites this paper
• Exaggerated IDO1 expression and activity in Langerhans cells from patients with atopic dermatitis upon viral stimulation: a potential predictive biomarker for high risk of Eczema herpeticum

  2015cites this paper
• Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch

  2015cites this paper
• Mechanisms of allergic diseases Cellular and molecular immunologic mechanisms in patients with atopic dermatitis

  year unknowncites this paper
• Allergologia et immunopathologia

  year unknowncites this paper